Matteo Pavan
Overview
Explore the profile of Matteo Pavan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paviotti G, Pavan M, Driutti M, Beorchia Y, Castriotta L, Risso F, et al.
Eur J Pediatr
. 2025 Feb;
184(3):208.
PMID: 39992455
To test the hypothesis that thoracic fluid content (TFC) by thoracic electrical bioimpedance would be higher in preterm infants with respiratory distress syndrome (RDS) both at birth and in the...
2.
Pavan M, Menin S, Dodaro A, Novello G, Cavastracci Strascia C, Sturlese M, et al.
J Chem Inf Model
. 2025 Jan;
65(3):1492-1513.
PMID: 39835670
During the last 20 years, the fragment-based drug discovery approach gained popularity in both industrial and academic settings due to its efficient exploration of the chemical space. This bottom-up approach...
3.
Tosh D, Pavan M, Clark A, Lammers J, Villano S, Marri S, et al.
J Med Chem
. 2024 Nov;
67(23):21264-21291.
PMID: 39589936
Rigidified nucleoside derivatives with (N)-methanocarba replacement of ribose have been repurposed as peripheral subtype-selective 5-HT serotonin receptor antagonists for heart and lung fibrosis and intestinal/vascular conditions. 4'-Cyano derivative (MRS8209; ,...
4.
Mukherjee M, Biesbrock D, Abramowitz L, Pavan M, Kumar B, Walter P, et al.
Nat Chem Biol
. 2024 Oct;
PMID: 39468349
Metabolic incorporation of chemically tagged monosaccharides is a facile means of tagging cellular glycoproteins and glycolipids. However, since the monosaccharide precursors are often shared by several pathways, selectivity has been...
5.
Costacurta F, Dodaro A, Bante D, Schoppe H, Peng J, Sprenger B, et al.
PLoS Pathog
. 2024 Sep;
20(9):e1012522.
PMID: 39259728
Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2 main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other...
6.
Tosh D, Pavan M, Cronin C, Pottie E, Wan T, Chen E, et al.
ACS Pharmacol Transl Sci
. 2024 Jul;
7(7):2154-2173.
PMID: 39022354
2-Arylethynyl (N)-methanocarba adenosine 5'-methylamides are selective A adenosine receptor (AR) agonists containing a preestablished receptor-preferred pseudoribose conformation. Here, we compare analogues having bulky 2-substitution, either containing or lacking an ethynyl...
7.
Pradhan B, Pavan M, Fisher C, Salmaso V, Wan T, Keyes R, et al.
J Med Chem
. 2024 Jul;
67(14):12221-12247.
PMID: 38959401
A adenosine receptor (AAR) positive allosteric modulators (PAMs) (2,4-disubstituted-1-imidazo[4,5-]quinolin-4-amines) allosterically increase the of AAR agonists, but not potency, due to concurrent orthosteric antagonism. Following mutagenesis/homology modeling of the proposed lipid-exposed...
8.
Fisher C, Pavan M, Salmaso V, Keyes R, Wan T, Pradhan B, et al.
Mol Pharmacol
. 2024 Jan;
105(3):213-223.
PMID: 38182432
This study describes the localization and computational prediction of a binding site for the A adenosine receptor (AAR) positive allosteric modulator 2-cyclohexyl-1-imidazo[4,5-c]quinolin-4-(3,4-dichlorophenyl)amine (LUF6000). The work reveals an extrahelical lipid-facing binding...
9.
Dodaro A, Pavan M, Menin S, Salmaso V, Sturlese M, Moro S
Front Mol Biosci
. 2023 Nov;
10:1294543.
PMID: 38028536
Ribonucleic acids are gradually becoming relevant players among putative drug targets, thanks to the increasing amount of structural data exploitable for the rational design of selective and potent binders that...
10.
Costacurta F, Dodaro A, Bante D, Schoppe H, Sprenger B, Moghadasi S, et al.
bioRxiv
. 2023 Oct;
PMID: 37808638
Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL/M) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and...